Aerocare to manage the marketing and sales of Cecoline 9, a 9-valent HPV vaccine, expanding beyond pharmaceuticals to strengthen access to preventative healthcare.
On 1 September 2026, Aerocare was appointed by Global Biotechnology Product Co., Ltd. (GBP), a company with the Government Pharmaceutical Organization (GPO) as a shareholder, to manage the marketing and sales of Cecoline 9, a 9-valent HPV vaccine indicated for women aged 11–45.
Under this appointment, Aerocare will be responsible for the marketing and sales management of Cecoline 9, with a focus on the private healthcare sector. Through this role, Aerocare aims to contribute to expanding access and providing greater opportunities for people to access HPV vaccination for cervical cancer prevention.
This appointment marks another important step in Aerocare’s continued growth and expansion within the healthcare industry. It reflects our commitment to building new capabilities, expanding our portfolio of healthcare solutions, and creating greater value across the healthcare ecosystem.
As Aerocare continues to grow, we remain focused on connecting people with quality healthcare products and innovative solutions that support disease prevention and better health outcomes.
We look forward to continuing our journey of growth and contributing to a healthier future for communities in Thailand.